A PYMNTS Company

Gilead Focuses On Cancer Treatments With $21B Immunomedics Deal

By  |  September 15, 2020

Gilead Sciences Inc. agreed to acquire Immunomedics Inc. for about $21 billion, a substantial premium for the maker of a promising breast-cancer therapy, and another big bet by Gilead that an innovative tumor-fighting drug can boost its fortunes.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The proposed $88-a-share deal values Immunomedics at more than twice its closing price of $42.25 on Friday. The New Jersey-based company makes a breast-cancer treatment called Trodelvy that gained approval from the U.S. Food and Drug Administration in April. Since then, its stock has soared on bets that the clearance could make Immunomedics an attractive takeover target.

    Trodelvy’s approval came after clinical trial data showed it beat back triple-negative breast cancer for almost four months longer than chemotherapy in patients getting the medication as a third line of therapy. The hard-to-treat disease — which accounts for about 10-15% of all breast cancers — doesn’t respond to many of the current treatment regimens. Chief Executive Officer Daniel O’Day said Gilead was also interested in the drug because of broad potential uses in bladder, lung and other tumor types.

    Full Content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.